MAIA Biotechnology, Inc. (MAIA)

USD 1.94

(-11.82%)

Total Liabilities Summary of MAIA Biotechnology, Inc.

  • MAIA Biotechnology, Inc.'s latest annual total liabilities in 2023 was 7.08 Million USD , up 101.73% from previous year.
  • MAIA Biotechnology, Inc.'s latest quarterly total liabilities in 2024 Q2 was 8.85 Million USD , down -38.83% from previous quarter.
  • MAIA Biotechnology, Inc. reported annual total liabilities of 3.51 Million USD in 2022, up 63.76% from previous year.
  • MAIA Biotechnology, Inc. reported annual total liabilities of 2.14 Million USD in 2021, down -9.18% from previous year.
  • MAIA Biotechnology, Inc. reported quarterly total liabilities of 8.85 Million USD for 2024 Q2, down -38.83% from previous quarter.
  • MAIA Biotechnology, Inc. reported quarterly total liabilities of 3.39 Million USD for 2023 Q2, down -14.94% from previous quarter.

Annual Total Liabilities Chart of MAIA Biotechnology, Inc. (2023 - 2019)

Historical Annual Total Liabilities of MAIA Biotechnology, Inc. (2023 - 2019)

Year Total Liabilities Total Liabilities Growth
2023 7.08 Million USD 101.73%
2022 3.51 Million USD 63.76%
2021 2.14 Million USD -9.18%
2020 2.36 Million USD 476.66%
2019 409.73 Thousand USD 0.0%

Peer Total Liabilities Comparison of MAIA Biotechnology, Inc.

Name Total Liabilities Total Liabilities Difference
AIM ImmunoTech Inc. 9.14 Million USD 22.495%
Ampio Pharmaceuticals, Inc. 2.37 Million USD -198.373%
Armata Pharmaceuticals, Inc. 142.02 Million USD 95.009%
Actinium Pharmaceuticals, Inc. 45.06 Million USD 84.269%
Azitra, Inc. 2.2 Million USD -221.9%
Can-Fite BioPharma Ltd. 3.74 Million USD -89.251%
Chromocell Therapeutics Corporation 6.54 Million USD -8.384%
Calidi Biotherapeutics, Inc. 18.25 Million USD 61.163%
CEL-SCI Corporation 17.31 Million USD 59.053%
iBio, Inc. 7.41 Million USD 4.327%
Lineage Cell Therapeutics, Inc. 38.99 Million USD 81.82%
Matinas BioPharma Holdings, Inc. 46.33 Million USD 84.699%
Navidea Biopharmaceuticals, Inc. 12.51 Million USD 43.353%
NovaBay Pharmaceuticals, Inc. 5.72 Million USD -23.94%
NanoViricides, Inc. 1.35 Million USD -421.745%
Oragenics, Inc. 1.79 Million USD -294.251%
BiomX Inc. 55.07 Million USD 87.128%
BiomX Inc. 55.07 Million USD 87.128%
Protalix BioTherapeutics, Inc. 50.86 Million USD 86.062%
Palatin Technologies, Inc. 10.85 Million USD 34.683%
Scorpius Holdings, Inc. 22.74 Million USD 68.829%